Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: A prospective clinical study

Respirology

Volumn 19, Issue 6, 2014, Pages 929-935

  Ferrer, Miquel ^a   Torres, Antoni ^a   Martínez, Raquel ^b   Ramírez, Paula ^c   Polverino, Eva ^a   Montull, Beatriz ^b   Sialer, Salvador ^a   Niederman, Michael S ^d   Agusti, Alvar ^a   Menéndez, Rosario ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b Department of Pneumology ^*  (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

community acquired pneumonia; inflammatory biomarker; inhaled corticosteroid; systemic inflammatory response; tumour necrosis factor alpha

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; C REACTIVE PROTEIN; CEPHALOSPORIN; CORTICOSTEROID; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; PROCALCITONIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

AGED; ARTICLE; ASTHMA; BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL STUDY; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; DISEASE SEVERITY; ENTEROBACTERIACEAE; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; LEGIONELLA PNEUMOPHILA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; OUTPATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RISK ASSESSMENT; SMOKING; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BLOOD; BRONCHITIS; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; COMPLICATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRONCHITIS; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PNEUMONIA; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904541031     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12324     Document Type: Article

References (37)

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et-al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007; 44 (Suppl. 2): S27-72.
2. Nelson S,. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest 2001; 119: 419S-425.
3. Kolling UK, Hansen F, Braun J, Rink L, Katus HA, Dalhoff K,. Leucocyte response and anti-inflammatory cytokines in community acquired pneumonia. Thorax 2001; 56: 121-125.
4. Endeman H, Meijvis SC, Rijkers GT, van Velzen-Blad H, van Moorsel CH, Grutters JC, Biesma DH,. Systemic cytokine response in patients with community-acquired pneumonia. Eur. Respir. J. 2011; 37: 1431-1438.
5. Skerrett SJ, Park DR,. Anti-inflammatory treatment of acute and chronic pneumonia. Semin. Respir. Infect. 2001; 16: 76-84.
6. Menendez R, Martinez R, Reyes S, Mensa J, Filella X, Marcos MA, Martinez A, Esquinas C, Ramirez P, Torres A,. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009; 64: 587-591.
7. Monton C, Ewig S, Torres A, El Ebiary M, Filella X, Rano A, Xaubet A,. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur. Respir. J. 1999; 14: 218-220.
8. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J,. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur. Respir. J. 2007; 30: 951-956.
9. Sibila O, Agusti C, Torres A,. Corticosteroids in severe pneumonia. Eur. Respir. J. 2008; 32: 259-264.
10. De Pascale G, Bello G, Antonelli M,. Steroids in severe pneumonia: a literature review. Minerva Anestesiol. 2011; 77: 902-910.
11. Malo de Molina R, Mortensen EM, Restrepo MI, Copeland LA, Pugh MJ, Anzueto A,. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur. Respir. J. 2010; 36: 751-757.
12. Chen D, Restrepo MI, Fine MJ, Pugh MJ, Anzueto A, Metersky ML, Nakashima B, Good C, Mortensen EM,. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am. J. Respir. Crit. Care Med. 2011; 184: 312-316.
13. Rutgers SR, Koeter GH, van der Mark TW, Postma DS,. Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5â€-monophosphate in COPD. Am. J. Respir. Crit. Care Med. 1998; 157: 880-886.
14. Sin DD, Lacy P, York E, Man SF,. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170: 760-765.
15. Sellares J, Lopez-Giraldo A, Lucena C, Cilloniz C, Amaro R, Polverino E, Ferrer M, Menendez R, Mensa J, Torres A,. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 2013; 187: 1241-1248.
16. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN,. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 1997; 336: 243-250.
17. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT,. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-382.
18. Man SF, Xuekui Z, Vessey R, Walker T, Lee K, Park D, Sin DD,. The effects of inhaled and oral corticosteroids on serum inflammatory biomarkers in COPD: an exploratory study. Ther. Adv. Respir. Dis. 2009; 3: 73-80.
19. Gutierrez P, Closa D, Piner R, Bulbena O, Menendez R, Torres A,. Macrophage activation in exacerbated chronic obstructive pulmonary disease with and without community-acquired pneumonia. Eur. Respir. J. 2010; 36: 285-291.
20. Taylor AE, Finney-Hayward TK, Quint JK, Thomas CM, Tudhope SJ, Wedzicha JA, Barnes PJ, Donnelly LE,. Defective macrophage phagocytosis of bacteria in COPD. Eur. Respir. J. 2010; 35: 1039-1047.
21. Gordon S,. Alternative activation of macrophages. Nat. Rev. Immunol. 2003; 3: 23-35.
22. Martinez FO, Sica A, Mantovani A, Locati M,. Macrophage activation and polarization. Front. Biosci. 2008; 13: 453-461.
23. Menendez R, Torres A, Zalacain R, Aspa J, Martin Villasclaras JJ, Borderias L, Benítez Moya JM, Ruiz-Manzano J, Rodríguez de Castro F, Blanquer J, et-al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960-965.
24. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, Schraeder P, Welte T, Hoeffken G,. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-1069.
25. Liapikou A, Polverino E, Ewig S, Cilloniz C, Marcos MA, Mensa J, Bello S, Martin-Loeches I, Menendez R, Torres A,. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur. Respir. J. 2012; 39: 855-861.
26. Torres A, Ewig S,. The strange case of community-acquired pneumonia in COPD. Chest 2011; 139: 483-485.
27. Sibila O, Laserna E, Mortensen EM, Anzueto A, Restrepo MI,. Inhaled corticosteroid effects on pneumonia severity and antimicrobial resistance. Respir. Care 2013; 58: 1489-1494.
28. Singanayagam A, Chalmers JD, Akram AR, Hill AT,. Impact of Inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur. Respir. J. 2011; 38: 36-41.
29. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J,. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775-789.
30. Calverley PM, Stockley RA, Seemungal TA, Hagan G, Willits LR, Riley JH, Wedzicha JA,. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139: 505-512.
31. Singh S, Amin AV, Loke YK,. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch. Intern. Med. 2009; 169: 219-229.
32. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E,. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 2407-2416.
33. Ek A, Larsson K, Siljerud S, Palmberg L,. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy 1999; 54: 691-699.
34. Janson C, Larsson K, Lisspers KH, Stallberg B, Stratelis G, Goike H, Jorgensen L, Johansson G,. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 2013; 346: f3306.
35. Edwards MR, Haas J, Panettieri RA Jr, Johnson M, Johnston SL,. Corticosteroids and beta2 agonists differentially regulate rhinovirus-induced interleukin-6 via distinct Cis-acting elements. J. Biol. Chem. 2007; 282: 15366-15375.
36. Skevaki CL, Christodoulou I, Spyridaki IS, Tiniakou I, Georgiou V, Xepapadaki P, Kafetzis DA, Papadopoulos NG,. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus. Clin. Exp. Allergy 2009; 39: 1700-1710.
37. Yamaya M, Nishimura H, Hatachi Y, Yasuda H, Deng X, Sasaki T, Kubo H, Nagatomi R,. Inhibitory effects of tiotropium on rhinovirus infection in human airway epithelial cells. Eur. Respir. J. 2012; 40: 122-132.